An Analysis Of Whether Higher Health Care Spending In The United States Versus Europe Is ‘Worth It’ In The Case Of Cancer
Open Access
- 1 April 2012
- journal article
- research article
- Published by Health Affairs (Project Hope) in Health Affairs
- Vol. 31 (4), 667-675
- https://doi.org/10.1377/hlthaff.2011.1298
Abstract
The United States spends more on health care than other developed countries, but some argue that US patients do not derive sufficient benefit from this extra spending. We studied whether higher US cancer care costs, compared with those of ten European countries, were "worth it" by looking at the survival differences for cancer patients in these countries compared to the relative costs of cancer care. We found that US cancer patients experienced greater survival gains than their European counterparts; even after considering higher US costs, this investment generated $598 billion of additional value for US patients who were diagnosed with cancer between 1983 and 1999. The value of that additional survival gain was highest for prostate cancer patients ($627 billion) and breast cancer patients ($173 billion). These findings do not appear to have been driven solely by earlier diagnosis. Our study suggests that the higher-cost US system of cancer care delivery may be worth it, although further research is required to determine what specific tools or treatments are driving improved cancer survival in the United States.Keywords
This publication has 20 references indexed in Scilit:
- Despite Criticism Of The FDA Review Process, New Cancer Drugs Reach Patients Sooner In The United States Than In EuropeHealth Affairs, 2011
- During The ‘Decade Of Vaccines,’ The Lives Of 6.4 Million Children Valued At $231 Billion Could Be SavedHealth Affairs, 2011
- Projections of the Cost of Cancer Care in the United States: 2010-2020JNCI Journal of the National Cancer Institute, 2011
- An economic evaluation of the war on cancerJournal of Health Economics, 2010
- Recent cancer survival in Europe: a 2000–02 period analysis of EUROCARE-4 dataThe Lancet Oncology, 2007
- Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995–99: results of the EUROCARE-4 studyThe Lancet Oncology, 2007
- Do the Large Benefits Justify the Large Costs of Adjuvant Breast Cancer Trastuzumab?Journal of Clinical Oncology, 2007
- How representative are the surveillance, epidemiology, and end results (SEER) Program cancer data of the United States?Cancer Causes & Control, 2004
- Overweight, Obesity, and Mortality from Cancer in a Prospectively Studied Cohort of U.S. AdultsThe New England Journal of Medicine, 2003
- Cancer statistics, 1999CA: A Cancer Journal for Clinicians, 1999